^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Starasid (cytarabine ocfosfate)
i
Other names: YNK01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nippon Kayaku
Drug class:
DNA synthesis inhibitor
Related drugs:
2d
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (clinicaltrials.gov)
P1, N=36, Recruiting, Children's Oncology Group | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2028
Trial completion date • Trial primary completion date
|
NF1 (Neurofibromin 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
|
RAS mutation • CBL mutation
|
cytarabine • methotrexate • leucovorin calcium • fludarabine IV • Rytelo (imetelstat) • Starasid (cytarabine ocfosfate)
5d
RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
8d
NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)
P1, N=30, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2029 | Trial primary completion date: Dec 2026 --> May 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
Chr t(15;17)
|
cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)
22d
AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov)
P3, N=9350, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2028 --> Mar 2026
Trial completion date
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
23d
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P2, N=222, Recruiting, National Cancer Institute (NCI) | Phase classification: P3 --> P2
Phase classification
|
ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
|
TruSight RNA Pan-Cancer Panel
|
dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
23d
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov)
P3, N=348, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
ABL1 T315I
|
dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • vincristine • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection
25d
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
P1, N=29, Not yet recruiting, Children's Oncology Group
New P1 trial
|
KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • CD4 (CD4 Molecule)
|
KMT2A rearrangement
|
cytarabine • methotrexate • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)
1m
LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2027 --> Nov 2033 | Trial primary completion date: Mar 2027 --> Feb 2031
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
1m
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
P2, N=53, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1)
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
1m
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
P2, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended
Trial suspension
|
CD20 (Membrane Spanning 4-Domains A1)
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
1m
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy (clinicaltrials.gov)
P2, N=70, Not yet recruiting, Uma Borate | Initiation date: Jan 2026 --> Apr 2026
Trial initiation date
|
NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
|
NPM1 mutation • KMT2A rearrangement
|
cytarabine • Komzifti (ziftomenib) • hydroxyurea • Starasid (cytarabine ocfosfate)
1m
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=87, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
Trial completion date
|
cytarabine • Starasid (cytarabine ocfosfate)
Share via
